Long-acting HIV prevention medicine study
Part of Infections clinical trials.
This study follows people taking a new long-acting HIV prevention injection called LA CAB (cabotegravir). Researchers want to understand how well it works, how people use it, and what side effects occur in real-world NHS clinics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are currently attending or newly starting at an NHS sexual health clinic
- You have been prescribed LA CAB (cabotegravir) for HIV prevention by your doctor
- Your most recent HIV tests came back negative
- You can give informed consent and commit to the study procedures
- You are not currently in another HIV prevention or vaccine trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
This trial tests a nurse-run program that makes it easier to get long-acting injectable PrEP (cabotegravir) for HIV prevention. It aims to see if nurses can start and provide this shot quickly at your regular clinic visits.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study is for people who are already taking or about to start long-acting injectable HIV PrEP (shots instead of daily pills). The goal is to learn about your experiences and preferences with this type of PrEP. It takes place in Louisville, Kentucky.
Hear when a new PrEP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.